Biogen is headed for the worst day in a decade after ending trial for blockbuster Alzheimer’s drug.
Shares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab, which it was developing in partnership with Japanese pharmaceutical company Eisai.
The company said in a statement that the decision to stop the phase 3 trial is based on an independent group's analysis showing that the trials were unlikely to"meet their primary endpoint." The recommendation to stop the studies was not based on safety concerns, Biogen said. "This disappointing news confirms the complexity of treating Alzheimer's disease and the need to further advance knowledge in neuroscience," said Michel Vounatsos, chief executive officer of Biogen, in a statement."We are incredibly grateful to all the Alzheimer's disease patients, their families and the investigators who participated in the trials and contributed greatly to this research.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
और पढो »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
और पढो »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
और पढो »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
और पढो »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street.
और पढो »
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday.
और पढो »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
और पढो »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open.
और पढो »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
और पढो »
Stocks inch higher, led by AppleStocks fell at the open after the Fed’s latest policy announcement sparked worries about the U.S. economy while shares of Biogen dragged down the health care sector.
और पढो »